0001104659-16-159822.txt : 20161130 0001104659-16-159822.hdr.sgml : 20161130 20161130194804 ACCESSION NUMBER: 0001104659-16-159822 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161129 FILED AS OF DATE: 20161130 DATE AS OF CHANGE: 20161130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aegerion Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001338042 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202960116 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 500-7867 MAIL ADDRESS: STREET 1: ONE MAIN STREET STREET 2: SUITE 800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Aegerion Pharmaceuticals Inc DATE OF NAME CHANGE: 20050906 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Scheer David CENTRAL INDEX KEY: 0001378585 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34921 FILM NUMBER: 162026504 MAIL ADDRESS: STREET 1: ACHILLION PHARMACEUTICALS STREET 2: 300 GEORGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06511 4 1 a4.xml 4 X0306 4 2016-11-29 1 0001338042 Aegerion Pharmaceuticals, Inc. AEGR 0001378585 Scheer David C/O AEGERION PHARMACEUTICALS, INC. ONE MAIN STREET, SUITE 800 CAMBRIDGE MA 02142 1 0 0 0 Common Stock 2016-11-29 4 D 0 10000 D 0 D Common Stock 2016-11-29 4 D 0 521350 D 0 I See Footnote Stock Option (Right to Buy) 17.64 2016-11-29 4 D 0 9988 D 2014-06-01 2021-06-01 Common Stock 9988 0 D Stock Option (Right to Buy) 15.00 2016-11-29 4 D 0 12854 D 2015-06-05 2022-06-05 Common Stock 12854 0 D Stock Option (Right to Buy) 64.73 2016-11-29 4 D 0 14700 D 2014-06-26 2023-06-26 Common Stock 14700 0 D Stock Option (Right to Buy) 32.55 2016-11-29 4 D 0 5012 D 2015-06-26 2024-06-26 Common Stock 5012 0 D Stock Option (Right to Buy) 17.98 2016-11-29 4 D 0 18000 D 2016-06-26 2025-06-26 Common Stock 18000 0 D Disposed of in exchange for 10,256 common shares of Novelion Therapeutics Inc. ("Novelion") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 14, 2016, by and among the Issuer, QLT Inc. ("QLT") and Isotope Acquisition Corp. ("Isotope"), pursuant to which Isotope was merged with and into the Issuer, effective November 29, 2016. Following completion of the merger, QLT was renamed "Novelion Therapeutics Inc." Disposed of in exchange for 534,696 common shares of Novelion pursuant to the Merger Agreement. Shares were held by Scheer Investment Holdings VII, LLC. The Reporting Person is the managing member of Scheer Investment Holdings VII, LLC. Mr. Scheer disclaimed beneficial ownership of such shares except to the extent of his proportionate pecuniary interest therein. Pursuant to the Merger Agreement, at the effective time of the merger, each option to acquire common stock of the Issuer that was outstanding and unexercised immediately prior to the effective time of the merger that had an exercise price per share equal to or greater than $1.88 (the product obtained by multiplying (i) the exchange ratio of 1.0256 by (ii) $1.83, the closing price of a common share of QLT on November 28, 2016) was cancelled without any payment or other consideration therefor. /s/ Jennifer Fitzpatrick, Attorney-in-fact 2016-11-30